NanoPac

Condition: Pancreatic adenocarcinoma

Eligibility

Key Inclusion Criteria

  • At least 18 years old
  • Confirmed locally advanced pancreatic adenocarcinoma
  • Has at least one lesion with a diameter of at least 1.5 cm but no more than 6 cm within 6 weeks of screening

Key Exclusion Criteria

  • Thrombotic or embolic events
  • Acute or subacute intestinal occlusion
  • History of inflammatory bowel disease
  • Previous or concurrent history of non-pancreatic cancer except for non-melanoma skin cancer

Full Study Name

Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects with Locally Advanced Pancreatic Adenocarcinoma (IRB no. 49989)

Summary

This study focuses on patients who have pancreatic cancer that cannot be removed with surgery and who have already received standard of care treatment (including IV chemotherapy). The purpose of the study is to determine whether the use of an investigational drug called NanoPac helps kill cancer cells in patients with pancreatic cancer. Researchers also aim to identify the dose of NanoPac that is best tolerated and causes the least side effects when injected directly into the tumor in the pancreas.

NanoPac is made of very small particles of another drug called paclitaxel, which is a chemotherapy drug approved by the U.S. Food and Drug Administration for other types of cancer. The use of Nanopac in this study is investigational.

Phase

Phase IIa

Principal Investigator

Simon Lo, MD

Contact
Liliana (Claudia) Bancila, PhD
Phone: 310-423-3872
Email: liliana.bancila@cshs.org